Frazier Healthcare VI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an investigational therapy. The company's lead product, Haduvio, is an oral extended-release formulation of nalbuphine currently undergoing Phase IIb/III clinical trials. Trevi Therapeutics is focused on addressing serious neurologically mediated conditions, including chronic pruritus, chronic cough associated with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in Parkinson's disease patients. The ongoing PRISM trial evaluates Haduvio's effectiveness in treating severe pruritus related to prurigo nodularis, highlighting its potential in managing conditions linked by a common pathophysiology involving opioid receptors in the nervous system. Founded in 2011, Trevi Therapeutics aims to provide innovative therapeutic solutions for patients with significant unmet medical needs.

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.

SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China.

Tricida, Inc. is a pharmaceutical company based in South San Francisco, California, established in 2013. The company is dedicated to the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a condition often associated with CKD, can hasten kidney deterioration and lead to serious complications such as muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, which aims to bind and remove acid from the gastrointestinal tract, thereby addressing the underlying metabolic issues and potentially slowing the progression of CKD.

Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Radionetics Oncology is a biopharmaceutical company dedicated to the discovery and development of innovative radiotherapeutics aimed at treating various oncology indications. The company specializes in creating non-peptide and small molecule agents that facilitate the targeted delivery of therapeutic radioisotopes to solid tumors. This focus positions Radionetics Oncology to address the growing need for advanced treatment options in oncology, enhancing the capabilities of medical professionals in managing cancer.

Gritstone Oncology is an immuno-oncology company focused on developing personalized cancer immunotherapies targeting various cancer types. Its lead product candidate, GRANITE, is undergoing Phase I/II clinical trials for the treatment of solid tumors, including metastatic non-small cell lung cancer, gastroesophageal, bladder, and colorectal cancers. Additionally, Gritstone is advancing SLATE, an off-the-shelf immunotherapy candidate also in Phase I/II trials, aimed at treating common solid tumors such as colorectal cancer and pancreatic cancer, particularly those with specific mutations. Founded in 2015 and headquartered in Emeryville, California, Gritstone leverages a blend of expertise in cancer biology and immunotherapy design, with a strategic collaboration with bluebird bio to enhance its therapeutic offerings.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

HilleVax is a clinical-stage biopharmaceutical company established in 2021 and based in Boston, Massachusetts. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a vaccine candidate that utilizes virus-like particle (VLP) technology aimed at preventing moderate-to-severe acute gastroenteritis caused by norovirus infection.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Hummingbird Bioscience Pte. Ltd. is a biotechnology company based in Singapore, specializing in the development of antibody-based therapeutics for cancer. Founded in 2014, it leverages advances in systems biology and a proprietary rational antibody discovery platform to create innovative biotherapeutics. The company focuses on a diverse pipeline of drug candidates, which includes lead assets such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both aimed at addressing significant unmet medical needs in oncology. Hummingbird Bioscience has established strategic collaborations with notable organizations such as Cancer Research UK and Amgen, and it has received a product development grant from the Cancer Prevention and Research Institute of Texas. The company's goal is to enhance treatment options for patients facing challenging cancer diagnoses through its cutting-edge research and development efforts.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that leverage its proprietary XTEN half-life extension platform, XPAT technology for analyzing protease activity in tumor environments, and ProTIA, an immuno-oncology therapeutic. Amunix aims to harness the immune system to develop safe and effective therapies for patients with solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, establishing strategic partnerships with several prominent organizations in the industry. Founded in 2006 and based in Mountain View, California, Amunix continues to advance its pipeline of novel biologics, focusing on improving treatment outcomes for cancer patients.

Seraxis is a private biotechnology company founded in March 2013, with operations in Singapore and the United States, and a GMP lab located in Germantown, Maryland. The company specializes in developing innovative cell replacement therapies aimed at treating insulin-dependent diabetes. Their primary focus is on creating a solution that allows for the production of insulin to manage glucose levels, providing patients with a long-term cure that does not necessitate immuno-suppression. Seraxis is dedicated to advancing its novel cell and encapsulation technologies to bring this treatment to clinical use as efficiently as possible.

CSafe specializes in the design and manufacture of cold chain solutions and mobile refrigeration units tailored for various sectors, including medical devices, pharmaceuticals, public health, military, and disaster relief. The company provides both passive and active containers for transporting temperature-sensitive materials, making it a key player in the logistics of sensitive goods. Additionally, CSafe offers a range of services such as leasing, active qualification and validation, training, and packaging qualification. With a global presence, the company serves its customers through a network of partners, service centers, and distributors, ensuring comprehensive support for cold chain logistics. Founded in 1989 and headquartered in Dayton, Ohio, CSafe is recognized for its unique offerings in active air cargo solutions and specialized services for cell and gene therapies.

Avadel Pharmaceuticals plc is a specialty pharmaceutical company based in Dublin, Ireland, with operations in the United States and France. The company focuses on developing innovative pharmaceutical products, particularly in the areas of urology, central nervous system disorders, and hospital settings. Avadel is advancing FT218, currently in Phase 3 clinical trials, aimed at treating narcolepsy patients experiencing excessive daytime sleepiness and cataplexy. Additionally, the company markets three sterile injectable medications used in hospitals: Akovaz for managing hypotension during anesthesia, Bloxiverz for reversing neuromuscular blockade after surgery, and Vazculep for treating significant hypotension. Avadel was originally founded as Flamel Technologies SA and rebranded in January 2017. It was incorporated in 2015 and continues to prioritize the development of safe and effective treatment options for patients.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Inipharm Inc. is a biopharmaceutical company based in Bellevue, Washington, established in 2018. The company specializes in discovering and developing therapies for severe liver diseases, particularly nonalcoholic steatohepatitis (NASH). Inipharm focuses on small-molecule drugs that target HSD17B13, a gene linked to various liver conditions. By modulating this gene's activity, Inipharm aims to reduce liver damage, inflammation, and fibrosis, addressing significant unmet medical needs in the treatment of liver diseases.

At Accuity Delivery Systems (ACCDS), we go beyond traditional Clinical Documentation Improvement (CDI) by taking a holistic approach to documenting, coding, & client education. Our services provide a supportive, collaborative and customizable approach to improving clinical documentation and bridging the gap between clinical care and complete, accurate and compliant coding. Specialties: Improved Clinical Documentation, Improved Clinical Documentation, Revenue Recognition Accuracy, Reduced Audit Risk, Improved Quality & Coordination of Care

Scholar Rock is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapies targeting growth factor signaling in serious diseases. The company’s lead product candidate, SRK-015, is a selective inhibitor of myostatin activation and is currently undergoing Phase II clinical trials for spinal muscular atrophy. Additionally, Scholar Rock is advancing SRK-181, which is in Phase I trials for treating cancers resistant to checkpoint inhibitors. The company employs a proprietary platform to design monoclonal antibodies that selectively modulate the activation of growth factors in disease microenvironments, addressing challenges associated with traditional growth factor inhibition. Scholar Rock is also developing a pipeline of candidates for a variety of conditions, including neuromuscular disorders, cancer, fibrosis, and anemia. Furthermore, the company has a collaboration with Gilead Sciences to explore specific inhibitors of transforming growth factor beta for fibrotic diseases. Founded in 2012, Scholar Rock aims to improve patient outcomes through its targeted therapeutic approach.

MBX Biosciences, Inc. is a biotechnology company based in Carmel, Indiana, specializing in the development of therapeutics for rare endocrine disorders. Founded in 2018, the company aims to address unmet medical needs by discovering and commercializing innovative treatments for endocrine diseases that affect hormonal regulation in the body. MBX Biosciences focuses on creating first-in-class therapies, particularly utilizing peptides to target rare genetic conditions related to glandular hormone secretion.

Lassen Therapeutics develops antibodies as potential treatments for fibrosis, rare diseases, and oncology. The company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor alpha (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be more effective than targeting other factors such as TGF-β and CTGF. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.

Lengo Therapeutics a biopharmaceutical company focused on the discovery and development of cancer treatments. Lengo works to identify several mutations in cancers that were not well addressed by existing therapeutics, helping medical practitioners and pharma companies to target driver mutations in oncology.

Dascena, Inc. is a technology company based in Oakland, California, specializing in the development of algorithm software for diagnostics and biomarkers. Founded in 2018, Dascena creates machine learning algorithms designed to enhance early disease intervention and improve patient care outcomes. Its primary product, AlgoDiagnostics, autonomously processes electronic health record data to identify conditions such as acute decompensation, sepsis, and acute kidney injury. By leveraging advanced algorithms, Dascena aims to facilitate timely medical responses and support healthcare professionals in delivering better patient care.

Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics for cancer treatment. The company specializes in creating prodrugs that leverage its proprietary XTEN half-life extension platform, XPAT technology for analyzing protease activity in tumor environments, and ProTIA, an immuno-oncology therapeutic. Amunix aims to harness the immune system to develop safe and effective therapies for patients with solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, establishing strategic partnerships with several prominent organizations in the industry. Founded in 2006 and based in Mountain View, California, Amunix continues to advance its pipeline of novel biologics, focusing on improving treatment outcomes for cancer patients.

SINCE ITS FOUNDING IN 1981, the Northfield, New Hampshire-based company has been a leader in solving the most difficult challenges in plastic component manufacturing and CNC machining. With the 2018 acquisition of Relius Medical (now EPTAM Precision Metals), EPTAM is now a single-source point of contact for precision manufacturing solutions in both plastics and metals. EPTAM's sales, engineering, manufacturing, and quality teams operate as an extension of the OEM's design and material engineering departments to establish solutions and specifications for a wide variety of precision-machining applications. With its record of providing the highest-quality, tightest-tolerance machined parts for mission-critical applications, the company serves leaders in the medical, semiconductor, and aerospace/defense industries to provide advanced solutions for emerging commercial technologies.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Epizyme, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the discovery, development, and commercialization of epigenetic medicines for cancer and other diseases. The company has developed Tazemetostat, which is approved for treating metastatic or locally advanced epithelioid sarcoma in the United States. Tazemetostat is also being investigated in various combinations for other conditions, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition, Epizyme is developing other therapeutic candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, as well as inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several notable organizations in the industry to enhance its research and development efforts. Incorporated in 2007, Epizyme aims to leverage advancements in epigenetic research to create innovative, targeted therapies for patients.

Bellus Health Inc. is a clinical-stage biopharmaceutical company based in Laval, Canada, that focuses on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. The company is also engaged in developing KIACTA™, a treatment for AA amyloidosis, a rare kidney disease, which has completed its Phase 3 study. KIACTA™ is also being explored for sarcoidosis, a serious inflammatory condition affecting the lungs. Additionally, Bellus Health is working on Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies underway. The company has a pipeline that includes research on AL amyloidosis, where amyloid protein accumulation leads to organ dysfunction.

IVERIC bio is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases, particularly age-related and orphan retinal conditions. The company is advancing several candidates, including Fovista, which has completed Phase IIb clinical trials as a combination treatment with anti-VEGF drugs for wet age-related macular degeneration (wet AMD). Additionally, IVERIC bio is developing ARC1905, a selective inhibitor of complement factor C5, which has completed Phase I/IIa clinical trials aimed at treating wet AMD. Founded in 2007 and headquartered in New York, IVERIC bio is dedicated to addressing unmet medical needs in the field of eye care.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

REGENXBIO Inc. is a clinical-stage biotechnology company focused on developing gene therapy product candidates that utilize its proprietary NAV Technology Platform, which is based on adeno-associated virus (AAV) gene delivery. This platform aims to address genetic defects and enable cells to produce therapeutic proteins or antibodies to combat various diseases. The company's lead candidate, RGX-314, is currently undergoing Phase I/IIa clinical trials for wet age-related macular degeneration. Other notable product candidates include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia, all in various stages of clinical trials. Additionally, REGENXBIO licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has partnered with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

MedData is a leading national provider of revenue cycle management and patient financial lifecycle solutions, including billing, coding, collections, and patient satisfaction.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

Comprehensive Pharmacy Services, Inc. (CPS) provides a broad range of pharmacy support services to over 800 hospitals and healthcare facilities across the United States. Founded in 1971 and headquartered in Memphis, Tennessee, CPS specializes in inpatient hospital pharmacy services, clinical consulting, and operational assessments. The company addresses various challenges faced by healthcare providers, including high drug costs, specialty pharmacy management, and operational efficiency. CPS also offers consulting solutions that encompass compliance, medication safety, sterile compounding, and pharmacy analytics. Through its extensive service offerings, CPS aims to enhance the quality and effectiveness of pharmacy operations within healthcare settings.

Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Imago BioSciences, based in San Carlos, California, is a biotechnology company focused on developing innovative therapies for hematologic diseases, including bone marrow failure, leukemia, myelodysplastic syndrome, and acute myelogenous leukemia. Founded in 2012, the company specializes in medicines that target genetic and epigenetic mechanisms to alter gene expression patterns, aiming to create transformative treatments for conditions that present significant challenges to patients and healthcare providers. By leveraging a skilled team and robust financial backing, Imago BioSciences is dedicated to addressing a select group of orphan diseases, striving to improve patient outcomes and enhance the quality of life for those affected.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Developer of antibiotic drugs intended to provide novel therapeutics for serious antibiotic-resistant infections. The company's drugs include the development of novel-class antibiotics to address the expanding problem of multi-drug resistant gram-negative bacteria, enabling patients to combat with potentially deadly pathogens.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Sojournix, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, that specializes in developing novel therapies aimed at addressing women's health and neuroendocrine disorders. Founded in 2016, the company is currently focused on the development of SJX-653, a selective neurokinin-3 (NK3) antagonist designed as a non-hormonal treatment for moderate to severe vasomotor symptoms. Through its innovative approach, Sojournix seeks to enhance the quality of life for patients affected by these conditions.

Atlanta Gastroenterology Associates is a leading gastroenterology practice located in Georgia, specializing in the detection and treatment of digestive and liver diseases, including colon cancer. The organization offers a wide range of services, including diagnosis and treatment of digestive disorders, gastroenterology surgery, anesthesia management, pathology services, and clinical research. By providing comprehensive digestive healthcare, Atlanta Gastroenterology Associates aims to deliver quality care to patients across Georgia and the southeastern United States at an affordable cost.

Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.

Krystal Biotech is a biopharmaceutical company based in Pittsburgh, Pennsylvania, focused on developing gene therapies for patients with rare skin diseases in the United States. Its primary candidate, beremagene geperpavec (B-VEC), is designed to treat dystrophic epidermolysis bullosa and has completed Phase I/II clinical trials. Additionally, the company is advancing KB105, which is in Phase I/II trials for autosomal recessive congenital ichthyosis, while KB301 and KB104 are in preclinical stages targeting aesthetic skin conditions and Netherton Syndrome, respectively. Krystal Biotech utilizes its proprietary STAR-D gene therapy platform to create innovative treatments that offer significant clinical benefits. Founded in 2015, the company aims to broaden its pipeline to address various dermatological conditions in the future.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

Mavupharma Inc., founded in 2016 and based in the United States, focuses on the development of innovative therapies aimed at treating cancer and infectious diseases. The company is engaged in creating non-nucleotide, conditional modulators of the STING pathway, which plays a crucial role in the immune response. As of July 2019, Mavupharma operates as a subsidiary of AbbVie Inc., benefiting from the larger organization's resources and expertise in the pharmaceutical industry.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Gritstone Oncology is an immuno-oncology company focused on developing personalized cancer immunotherapies targeting various cancer types. Its lead product candidate, GRANITE, is undergoing Phase I/II clinical trials for the treatment of solid tumors, including metastatic non-small cell lung cancer, gastroesophageal, bladder, and colorectal cancers. Additionally, Gritstone is advancing SLATE, an off-the-shelf immunotherapy candidate also in Phase I/II trials, aimed at treating common solid tumors such as colorectal cancer and pancreatic cancer, particularly those with specific mutations. Founded in 2015 and headquartered in Emeryville, California, Gritstone leverages a blend of expertise in cancer biology and immunotherapy design, with a strategic collaboration with bluebird bio to enhance its therapeutic offerings.

Alteon Health, LLC is a company based in The Woodlands, Texas, that specializes in providing outsourced healthcare practice management services specifically for emergency departments and hospital-based urgent care centers. The organization is dedicated to advancing healthcare by focusing on patient-centered care, fostering physician-led innovation, and implementing data-driven practices. Additionally, Alteon Health seeks to establish strong partnerships within the healthcare sector to enhance service delivery and improve patient outcomes.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. The company's primary focus is on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials aimed at treating nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K acts as a next-generation insulin sensitizer, targeting the underlying mechanisms of NASH. Founded in 2015 and initially known as Octeta Therapeutics, Cirius Therapeutics is headquartered in San Diego, California.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. The company's lead product candidate, ARQ-151, is a topical cream formulation of roflumilast currently undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. In addition, Arcutis is advancing ARQ-154, a topical foam formulation of ARQ-151 aimed at treating seborrheic dermatitis and scalp psoriasis, as well as ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory skin conditions. Another candidate, ARQ-255, is being developed to penetrate deeper into the skin to address inflammation in alopecia areata. Founded in 2016 and located in Westlake Village, California, Arcutis Biotherapeutics was formerly known as Arcutis, Inc. before its name change in October 2019.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Recognized as the number one orthopedic group since 2012 by Ranking Arizona, The CORE Institute, was founded to fulfill a vision of excellence in patient care encompassing the entire spectrum of musculoskeletal and neurosciences care. Consistent with our mission, The CORE Institute delivers the best in musculoskeletal and neurological care, built upon a foundation of pioneering research, academics, community service, and a passion for excellence in patient care. It is now one of the premier patient care destinations in the World and cares for patients from around the globe.

Matrx Medical Network specializes in providing in-home health risk assessment services for Medicare Advantage plans. The company conducts one-on-one evaluations carried out by licensed Nurse Practitioners who perform non-invasive physical exams, gather detailed medical histories, and assess the member's living conditions and medications. These assessments are designed to identify risk factors that may require further medical attention, and the Nurse Practitioners also offer health information and recommendations for additional evaluations. Established in 2001, Matrx has become one of the largest providers of prospective health assessments in the United States, completing over 224,000 assessments in 2012 alone. With its headquarters in Scottsdale, Arizona, and a member outreach center in Clearwater, Florida, Matrx operates across more than 30 states, delivering comprehensive care management services to enhance the health of its members. The company is owned by Welsh, Carson, Anderson & Stowe.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company's lead programs include ALPN-101, an antagonist targeting the inducible T cell costimulator and CD28 pathways for autoimmune and inflammatory diseases, and ALPN-202, which combines programmed cell death protein ligand 1 and cytotoxic T-lymphocyte associated protein 4 antagonism with PD-L1 dependent CD28 costimulation for cancer treatment. Additionally, Alpine has a collaboration with Kite Pharma, Inc. to develop immunotherapies that target the immune synapse for cancer therapy. The company utilizes a proprietary platform to transform native immune system proteins into innovative, multi-targeted therapeutics.

Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). Under a collaborative research and development agreement with Dr. Steven A. Rosenberg at the National Cancer Institute, we are investigating our our lead product candidate, LN-144, in the treatment of stage 4 metastatic melanoma. In clinical trials, LN-144 has demonstrated curative potential in patients with metastatic melanoma, and it may also be applicable to a wide range of other solid tumors.

Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasis’ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for the treatment of diseases affecting hospitalized patients. The company's primary product in development is ZOLYD, an investigational injectable antibiotic aimed at addressing serious and life-threatening infections caused by multi-drug resistant gram-negative and gram-positive bacteria. Founded in 2013, Zavante Therapeutics operates as a subsidiary of Nabriva Therapeutics plc, with a commitment to improving patient outcomes in critical care settings.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Gritstone Oncology is an immuno-oncology company focused on developing personalized cancer immunotherapies targeting various cancer types. Its lead product candidate, GRANITE, is undergoing Phase I/II clinical trials for the treatment of solid tumors, including metastatic non-small cell lung cancer, gastroesophageal, bladder, and colorectal cancers. Additionally, Gritstone is advancing SLATE, an off-the-shelf immunotherapy candidate also in Phase I/II trials, aimed at treating common solid tumors such as colorectal cancer and pancreatic cancer, particularly those with specific mutations. Founded in 2015 and headquartered in Emeryville, California, Gritstone leverages a blend of expertise in cancer biology and immunotherapy design, with a strategic collaboration with bluebird bio to enhance its therapeutic offerings.

Calibrium is an emerging privately held biopharmaceutical company focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, Calibrium’s Chief Executive Officer, and Richard DiMarchi, PhD, Calibirum’s Chief Scientific Officer.

AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating patients suffering from pain, particularly in relation to opioid medications. The company utilizes its proprietary DETERx platform technology, which enhances the safety and extended-release properties of medications while minimizing the risk of misuse through methods such as chewing, crushing, and injecting. Among its key offerings is Xtampza ER, an abuse-deterrent, extended-release formulation of oxycodone, alongside Nucynta ER and Nucynta IR, which are formulations of tapentadol designed for managing severe and moderate to severe pain, respectively. Collegium focuses on addressing the challenges related to the non-medical use of prescription drugs by emphasizing tamper-resistant features and innovative delivery systems in its product portfolio. Founded in 2002 and based in Stoughton, Massachusetts, the company aims to provide effective pain management solutions while prioritizing patient safety.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Laguna Pharmaceuticals Inc. develops and markets drugs and small molecule pharmaceuticals vanoxerine, a therapeutic drug candidate for the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company was formerly known as ChanRx Corp. and changed its name to Laguna Pharmaceuticals Inc. in February, 2015. Laguna Pharmaceuticals Inc. was founded in 2006 and is based in La Jolla, California.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Imago BioSciences, based in San Carlos, California, is a biotechnology company focused on developing innovative therapies for hematologic diseases, including bone marrow failure, leukemia, myelodysplastic syndrome, and acute myelogenous leukemia. Founded in 2012, the company specializes in medicines that target genetic and epigenetic mechanisms to alter gene expression patterns, aiming to create transformative treatments for conditions that present significant challenges to patients and healthcare providers. By leveraging a skilled team and robust financial backing, Imago BioSciences is dedicated to addressing a select group of orphan diseases, striving to improve patient outcomes and enhance the quality of life for those affected.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer, particularly in the fields of hematology and oncology. Its lead candidate, momelotinib, is a selective JAK1, JAK2, and ACVR1 inhibitor that has been evaluated in two Phase 3 trials for myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, currently undergoing two Phase 1/2 clinical trials to explore its potential as a monotherapy and in combination with other therapies. Additionally, Sierra is developing SRA141, a small molecule inhibitor of cell division cycle 7 kinase, which is in preclinical research stages. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology retains global commercialization rights for its product candidates and aims to achieve successful registration and commercialization of its innovative therapies targeting the DNA Damage Response network.

PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.

PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.

Semnur Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development of innovative non-opioid medications aimed at treating lumbar radicular pain. The company focuses on creating products that address the needs of pain management practitioners and their patients, particularly those suffering from back pain. By prioritizing clinical and commercial development, Semnur aims to enhance the efficacy and safety of pain management therapies, ultimately improving treatment outcomes for underserved patient populations.

Alcresta Therapeutics, Inc. develops and commercializes enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's primary offering, RELiZORB, is a digestive enzyme cartridge designed to replicate the function of pancreatic lipase for adults on enteral tube feeding who struggle to break down and absorb fats. Established in 2011 and based in Warren, New Jersey, Alcresta focuses on innovative, point-of-care nutritional products that enhance nutrition and manage health conditions for various populations, including infants, aging adults, and individuals with acute or chronic diseases. The company leverages its expertise in both adult and pediatric nutrition, along with protein manufacturing and regulatory knowledge, to address the unmet nutritional needs of those with compromised health.

Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. The company's most advanced drug candidate, ACHN-490, has demonstrated a positive safety and dosing profile in Phase 1 clinical testing and displayed broad spectrum efficacy in preclinical studies against systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria (e.g., E. coli, K. pneumoniae, and P. aeruginosa) and MRSA. In addition, the company is pursuing preclinical programs in several other areas of interest to combat the global emergence of bacterial resistance.

Acerta Pharma B.V. offers drug discovery and development services for oncology and autoimmune diseases. It offers late stage development, and early stage development. The company was founded in 2013 and is based in Oss, the Netherlands. Acerta Pharma B.V. operates as a subsidiary of AstraZeneca PLC.

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness. They have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, in order to revolutionize the traditional glaucoma treatment and management paradigm. They launched the iStent®, their first MIGS device, in the United States in 2012. They are leveraging their platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. They believe the iStent® is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, they completed an initial public offering and their shares are now traded on the New York Stock Exchange under the ticker symbol “GKOS”. The company was founded in 1998 and is based in San Clemente, California.

Scilex Holding Company, through its subsidiary Scilex Pharmaceuticals, Inc., is engaged in the development and commercialization of pharmaceutical products aimed at pain management. The company specializes in acquiring late-stage clinical products, including both generic and branded generic medications, with a particular focus on innovative delivery methods such as transdermal patches. These products are designed to address pain conditions, notably post-herpetic neuralgia. Scilex operates within the United States, Canada, Mexico, and Latin America, serving a diverse customer base through wholesalers, distributors, and retailers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Scilex is dedicated to providing effective solutions for patients suffering from various pain conditions.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Alcresta Therapeutics, Inc. develops and commercializes enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's primary offering, RELiZORB, is a digestive enzyme cartridge designed to replicate the function of pancreatic lipase for adults on enteral tube feeding who struggle to break down and absorb fats. Established in 2011 and based in Warren, New Jersey, Alcresta focuses on innovative, point-of-care nutritional products that enhance nutrition and manage health conditions for various populations, including infants, aging adults, and individuals with acute or chronic diseases. The company leverages its expertise in both adult and pediatric nutrition, along with protein manufacturing and regulatory knowledge, to address the unmet nutritional needs of those with compromised health.

Collegium Pharmaceutical is a specialty pharmaceutical company that develops and commercializes products aimed at treating patients suffering from pain, particularly in relation to opioid medications. The company utilizes its proprietary DETERx platform technology, which enhances the safety and extended-release properties of medications while minimizing the risk of misuse through methods such as chewing, crushing, and injecting. Among its key offerings is Xtampza ER, an abuse-deterrent, extended-release formulation of oxycodone, alongside Nucynta ER and Nucynta IR, which are formulations of tapentadol designed for managing severe and moderate to severe pain, respectively. Collegium focuses on addressing the challenges related to the non-medical use of prescription drugs by emphasizing tamper-resistant features and innovative delivery systems in its product portfolio. Founded in 2002 and based in Stoughton, Massachusetts, the company aims to provide effective pain management solutions while prioritizing patient safety.

Kalidex Pharmaceuticals, Inc. manufactures pharmaceuticals. The company was incorporated in 2010 and is based in Menlo Park, California.

Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.

Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. Its proprietary technological approach enables the design, formulation, and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. It was founded in 2011 and headquartered in Newton, Massachusetts.

Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.

PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.

Silvergate Pharmaceuticals, Inc. develops and commercializes pediatric medications. The company markets its products under the Epaned brand name. Silvergate Pharmaceuticals, Inc. was incorporated in 2010 and is based in Greenwood Village, Colorado. As of May 31, 2019, Silvergate Pharmaceuticals, Inc. operates as a subsidiary of CutisPharma Inc.